Skip Navigation



Hum. Reprod. Advance Access published online on February 12, 2004
Human Reproduction, doi:10.1093/humrep/deh157
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/4/788    most recent
deh157v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aknin-Seifer, I. E.
Right arrow Articles by Levy, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aknin-Seifer, I. E.
Right arrow Articles by Levy, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received July 18, 2003
Revised November 25, 2003
Accepted December 3, 2003

Opinion

Y chromosome microdeletion screening in infertile men in France:a survey of French practice based on 88 IVF centres

Isabelle Esther Aknin-Seifer 1, Hervé Lejeune 2, Renaud Laurian Touraine 3, and Rachel Levy 4*

1 Laboratoire de Biologie de la Reproduction, Hôpital Nord, 42055 Saint Etienne, France; Laboratoire de Génétique Moléculaire, Faculté de Médecine, Saint Etienne, France
2 Département de Médecine de la Reproduction, Hôpital Edouard Herriot, Lyon, France
3 Laboratoire de Génétique Moléculaire, Faculté de Médecine, Saint Etienne, France
4 Laboratoire de Biologie de la Reproduction, Hôpital Nord, 42055 Saint Etienne, France

* To whom correspondence should be addressed. E-mail: rachel.levy{at}chu-st-etienne.fr.


  Abstract

Y chromosome microdeletion screening is advised in cases of severely impaired spermatogenesis. Improvements in molecular biological techniques have made diagnosis more accessible in routine analysis. However, Y chromosome microdeletions are not diagnosed in all IVF centres. The aim of the present study was to determine the regulatory (indications, financing) and performance (methods, invoicing) conditions required for this analysis, in France. Microdeletion detection was found to be spreading fast and consistantly. It therefore seems necessary for a consensus to be reached on indications, with a view to a standardized technique, with a common effort of experts in the field. Financial management by the French Health Insurance bodies (Sécurité Sociale) would be an essential step towards routine adoption. Lastly, the answers to our questionnaire revealed a strong demand for information concerning this analysis.

Key words: Key words: France/male infertility/microdeletions/survey/Y chromosome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.